Eurofins Scientific Shares Jump 5.74% at Opening, Supported by BNP Paribas

Strong Opening Performance and Analyst Upgrade

Eurofins Scientific's stock displayed a gain of 5.74% at the opening this Monday, January 5, 2026, reaching 65.56 euros up from 62 euros the previous day. BNP Paribas Exane announced this morning that it had raised its target price from 51.50 to 75 euros and upgraded its recommendation from 'underperform' to 'outperform'. Trading volumes remained moderate with only 0.05% of capital traded, indicating a still cautious move by investors. This increase follows a positive week already up by 5.5%, bringing the annual performance to a solid 34.98%. Over the past three months, however, the stock has limited its advance to 4.23%, reflecting the autumn's turbulence marked by mixed quarterly results. The price has now significantly surpassed the resistance threshold set at 62.40 euros, a technical level that had been a blocking point in recent weeks. This bullish acceleration occurs in a context where the group had confirmed its 2025 targets at the end of October, despite an unfavorable exchange rate environment with an expected impact of 1.6% on revenue if the USD/EUR rate were to hold. The last target price increase by Bernstein in mid-December, raised from 71.20 to 72.30 euros with a maintained 'outperform' recommendation, had already supported the stock which was then trading around 60 euros.

Technical Analysis Indicates Acceleration Phase

Technical analysis reveals a stock in full acceleration phase after several weeks of consolidation. The RSI has reached 89, a significant overheating level that reflects the vigor of buying but also raises questions about the short-term sustainability of this progression rate. This indicator, which measures the relative strength of the movement, usually signals a technical correction risk when it exceeds 70. The MACD presents an encouraging configuration with a positive histogram at 0.32, resulting from the recent bullish crossover of the MACD line at 1.00 above the signal line at 0.68. This configuration suggests momentum that could continue in the upcoming sessions, although caution is advised given the high level of the RSI. The price is now trading above its 50 and 200 session moving averages, both set at 59.64 euros, confirming a fundamentally constructive trend. The Bollinger Bands, which frame the stock's fluctuations between 55.65 and 63.98 euros, show that the price is breaking out from the top of this corridor, a sign of increasing upward volatility. The negative beta coefficient of -0.10 confirms the stock's independence from the general movements of the Paris market.

Sector Performance and Financial Forecasts

The Food & Feed and Environment Testing activities continue to drive the commercial dynamics of the group, particularly in Europe and North America, offsetting the persistent weakness of the BioPharma segment whose organic growth had fallen to only 0.4% in the third quarter from 1.5% in the second. Analyst consensus estimates earnings per share of 3.46 euros in 2025 and 3.90 euros in 2026, while revenue is expected to reach 7.3 billion euros for the year. The group posted revenue of 5.415 billion euros for the first nine months of 2025, up by 5.3% including 4% organic, slightly below market expectations of 4.4%. The target price raised by Bernstein to 72.30 euros now offers a potential upside of about 10% compared to the current price of 65.56 euros. The group also continues its active share buyback program, with 30,000 shares acquired between December 22 and 24 at an average price of 61.63 euros, and 90,000 shares between December 15 and 19 at an average of 59.43 euros. These operations reflect the management's confidence in the group's prospects and mechanically contribute to supporting the stock price.